/* mobile /* end mobile MEDDESKTOP

Thursday, December 04, 2014

Be Informed About Avian Influenza In British Colombia, Canada

Avian influenza (AI) is a contagious viral infection that can affect several species of food producing birds as well as pet birds and wild birds. AI viruses can be classified into two categories: low pathogenicity (LPAI) and highly pathogenic (HPAI) forms, based on the severity of the illness caused in birds.
Avian influenza viruses, such as the highly pathogenic H5N1 virus present in Asia, may, on rare occasions, cause disease in humans. Transmission to humans has occurred through close contact with infected birds or heavily contaminated environments.
In Canada, highly pathogenic avian influenza and low pathogenicity H5 and H7 avian influenza viruses are considered to be Notifiable Avian Influenza, which is a reportable disease under the Health of Animals Act. All cases must be reported to the Canadian Food Inspection Agency (CFIA).
More Info at CFIA

Wednesday, December 03, 2014

The Canadian Food Inspection Agency (CFIA) Works To Control Avian Influenza In British Columbia

 After testing by the Province of British Columbia, CIFA has confirmed the presence of H5 avian influenza on two farms in the Fraser Valley; a turkey farm in Abbotsford and a broiler breeder farm in Chilliwack.

CFIA continues avian influenza investigation in British Columbia

The Canadian Food Inspection Agency (CFIA) is continuing its investigation into an outbreak of avian influenza on two farms in British Columbia's Fraser Valley.
The two farms continue to be under quarantine to control disease spread, and two additional farms in the Fraser Valley have been placed under quarantine today. These farms were determined to be at high risk since they received birds from one of the original farms. Birds on these new farms were also showing signs of illness.
As avian influenza is highly contagious and can spread rapidly, it is possible that additional at-risk farms may be identified in the coming days. Poultry farmers are encouraged to report any suspicious symptoms to the CFIA.
The CFIA will continue to advise the public and the poultry industry if additional farms are confirmed to be affected.
Testing continues in order to confirm pathogenicity. Results are expected within days.
In the coming days, the CFIA will humanely euthanize and dispose of all birds on the infected premises in accordance with provincial environmental regulations and internationally accepted disease control guidelines.
When animals affected by a disease are ordered destroyed by the CFIA under the Health of Animals Act, the farmer is also informed that they will receive compensation. The CFIA is dedicated to working directly with affected producers so that the compensation process runs as smoothly as possible.
For animals ordered destroyed, the CFIA bases compensation amounts on the animal's market value (up to a maximum amount as stipulated in the Compensation for Destroyed Animals Regulations), taking into consideration factors such as genetic background, age and production records. For example, a normal eating chicken is assigned a rate of $20 per bird, a breeding chicken is $1200 per bird, a turkey is $70 per bird, and a breeding turkey is $1050 per bird. Please refer to the Schedule in the Regulations for accurate amounts.
Normally, a producer can expect compensation in 6 to 10 weeks.
Beyond the CFIA's compensation, other financial assistance may be available through programs administered by Agriculture and Agri-Food Canada, and, in some cases, provincial or territorial governments. Costs and losses considered by these programs may include business disruption and other extraordinary costs incurred due to disease.
Avian influenza viruses do not pose risks to food safety when poultry and poultry products are properly handled and cooked. Avian influenza rarely affects humans that do not have consistent contact with infected birds. Public health authorities stand ready to take precautionary measures as warranted.
The CFIA has mobilized all available resources to manage this situation. The Agency continues to work closely with the Province of British Columbia, the owners of the infected birds, and the poultry industry to manage this outbreak.

Tuesday, December 02, 2014

CDC Rapid Ebola Preparedness (REP) teams have assessed more than 50 facilities in 15 states and D.C.

The Hospitals Equipped With Ebola Treatment Centers In USA As Of 12/2/2014

This list will be updated weekly. The 35 hospitals with Ebola treatment centers listed alphabetically state-wise as of 12/2/2014 are :
  • Kaiser Oakland Medical Center; Oakland, California
  • Kaiser South Sacramento Medical Center; Sacramento, California
  • University of California Davis Medical Center; Sacramento, California
  • University of California San Francisco Medical Center; San Francisco, California
  • Emory University Hospital; Atlanta, Georgia
  • Ann & Robert H. Lurie Children’s Hospital of Chicago; Chicago, Illinois
  • Northwestern Memorial Hospital; Chicago, Illinois
  • Rush University Medical Center; Chicago, Illinois
  • University of Chicago Medical Center; Chicago, Illinois
  • Johns Hopkins Hospital; Baltimore, Maryland
  • University of Maryland Medical Center; Baltimore, Maryland
  • National Institutes of Health Clinical Center; Bethesda, Maryland
  • Allina Health’s Unity Hospital; Fridley, Minnesota
  • Children’s Hospitals and Clinics of Minnesota - Saint Paul campus; St. Paul, Minnesota
  • Mayo Clinic Hospital - Rochester, Saint Marys Campus; Rochester, Minnesota
  • University of Minnesota Medical Center, West Bank campus, Minneapolis, Minnesota
  • Nebraska Medicine - Nebraska Medical Center; Omaha, Nebraska
  • North Shore System LIJ/Glen Cove Hospital; Glen Cove, New York
  • Montefiore Health System; New York City, New York
  • New York-Presbyterian/Allen Hospital; New York City, New York
  • NYC Health and Hospitals Corporation/HHC Bellevue Hospital Center; New York City, New York
  • Robert Wood Johnson University Hospital; New Brunswick, New Jersey
  • The Mount Sinai Hospital; New York City, New York
  • Children's Hospital of Philadelphia; Philadelphia, Pennsylvania
  • Hospital of the University of Pennsylvania; Philadelphia, Pennsylvania
  • University of Texas Medical Branch at Galveston; Galveston, Texas
  • Methodist Hospital System in collaboration with Parkland Hospital System and the University of Texas Southwestern Medical Center; Richardson, Texas
  • University of Virginia Medical Center; Charlottesville, Virginia
  • Virginia Commonwealth University Medical Center; Richmond, Virginia
  • Children’s Hospital of Wisconsin, Milwaukee; Milwaukee, Wisconsin
  • Froedtert & the Medical College of Wisconsin – Froedtert Hospital, Milwaukee; Milwaukee, Wisconsin
  • UW Health – University of Wisconsin Hospital, Madison, and the American Family Children’s Hospital, Madison; Madison, Wisconsin
  • MedStar Washington Hospital Center; Washington, D.C.
  • Children's National Medical Center; Washington, D.C.
  • George Washington University Hospital; Washington, D.C.

Monday, December 01, 2014

World Aids Day 2014. "Focus, Partner, Achieve: An AIDS-Free Generation"

On December 1, the whole world observe World AIDS Day. Mainly to raise awareness of the global impact of HIV/AIDS, to share the pains, achievements of those affected by it, both triumphant and defeated. Most importantly to raise awareness and achieve more positive results in the upcoming year. It is estimated that closer to 35 million people are living with HIV/AIDS worldwide. The theme for World AIDS Day 2014 – “Focus, Partner, Achieve: An AIDS-Free Generation” – reflects the drive to focus on interventions proven to work and to partner with a broad range of stakeholders to achieve control of the HIV epidemic and, ultimately, an AIDS-free generation.

Tuesday, November 25, 2014

Do not purchase or use Black Storm, FDA Recommendation

Black Storm: Public Notification - Undeclared Drug Ingredient

[Posted 11/24/2014]
AUDIENCE: Consumer
ISSUE: FDA is advising consumers not to purchase or use Black Storm. FDA laboratory analysis confirmed that Black Storm contains sildenafil, the active ingredient in the FDA-approved prescription drug Viagra, used to treat erectile dysfunction (ED). This undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.
BACKGROUND: Black Storm is a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.
RECOMMENDATION: Do not purchase or use Black Storm.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
  • Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
[11/24/2014 - Public Notification - FDA]
[11/24/2014 - Tainted Sexual Enhancement Products - FDA]

FDA Drug Safety Communication Regarding Biogen Idec's Tecfidera (dimethyl fumarate)

Tecfidera (dimethyl fumarate) by Biogen Idec: Drug Safety Communication - Case of Rare Brain Infection PML Reported

[Posted 11/25/2014]
AUDIENCE: Neurology
ISSUE: FDA is warning that a patient with multiple sclerosis (MS) who was being treated with Tecfidera (dimethyl fumarate) developed a rare and serious brain infection called progressive multifocal leukoencephalopathy (PML), and later died. The patient who died was not taking any other drugs that affect the immune system or drugs that are thought to be associated with PML. As a result, information describing this case of PML is being added to the Tecfidera drug label.
PML is a rare and serious brain infection caused by the John Cunningham (JC) virus. The JC virus is a common virus that is harmless in most people but can cause PML in some patients who have weakened immune systems.
See the FDA Drug Safety Communication for additional clinical information about this case.

  • Tecfidera is a drug used to treat relapsing forms of multiple sclerosis (MS), a brain and spinal cord disease in which patients experience multiple episodes of weakness, numbness, and other nervous system signs and symptoms that partially or completely resolve overs weeks or months. Patients may develop persistent symptoms and disability over time.
  • Approximately 4,000 patients have taken Tecfidera in MS clinical trials, including 1,000 patients treated for at least 4 years. Biogen reports that more than 100,000 patients with MS worldwide have taken Tecfidera since FDA approved it in 2013.


Related Posts Widget for Blogs by LinkWithin